semaglutide patent expiry date opens door to GLP-1 generics in Canada Looming GLP-1 drug patent expirations

The slowdown came fast, steadily, and relentlessly, as seen in Intuitives subsequent quarterly commentary: Q323: In bariatrics, we continued to see double digit growth albeit at a modestly lower growth rate compared to Q2 Q423: We saw a continued deceleration in growth throughout 2023, likely the result of the uptake of GLP-1 drugs. Q124: Bariatric procedure growth continued to moderate and was flat year-over-year

A qualified doctor should determine the exact number and frequency for safe and effective results

Specific immunotherapy ameliorates ulcerative colitis

A slow, steady injection over 5 to 10 seconds distributes the solution more evenly and reduces trauma